Anti-CD19 CAR T-cell therapy is FDA-approved for B-cell precursor acute lymphoblastic leukemia (B-ALL) and under investigation for the treatment of AML with antigen targets such as CD33 and CD123. This evidence concerns the gene CD33 and acute myeloid leukemia.